| Document Type
|
:
|
BL
|
| Record Number
|
:
|
594309
|
| Doc. No
|
:
|
b423528
|
| Title & Author
|
:
|
Handbook of Therapeutic Antibodies
|
| Edition Statement
|
:
|
2nd ed
|
| Publication Statement
|
:
|
[England] :: Wiley Blackwell,, 2014
|
| Page. NO
|
:
|
1 online resource (2333 p.)
|
| ISBN
|
:
|
3527682422 (electronic bk.)
|
|
|
:
|
: 3527682430 (electronic bk.)
|
|
|
:
|
: 3527682449 (electronic bk.)
|
|
|
:
|
: 3527682457 (electronic bk.)
|
|
|
:
|
: 9783527682423 (electronic bk.)
|
|
|
:
|
: 9783527682430 (electronic bk.)
|
|
|
:
|
: 9783527682447 (electronic bk.)
|
|
|
:
|
: 9783527682454 (electronic bk.)
|
|
|
:
|
9783527329373
|
| Notes
|
:
|
5.4.3.4 Germline Frameworks
|
| Contents
|
:
|
Handbook of Therapeutic Antibodies; Contents; Quick Reference List of Antibodies by International Nonproprietary Name; Quick Reference List of Antibodies by Brand Name; A Greeting by the Editors; Foreword to the First Edition; Foreword to the Second Edition; List of Contributors; Abbreviations; Appendix: Marketed Monoclonal Antibodies Compendium; Volume I: Defining the Right Antibody Composition; Chapter 1 Therapeutic Antibodies -- from Past to Future; 1.1 An Exciting Start -- and a Long Trek; 1.2 The Gold Rush; 1.3 Success and Setbacks; 1.4 The Gleaming Horizon; References; Further Reading
|
|
|
:
|
5.1 Introduction5.2 History of Humanization; 5.3 CDR-Grafting; 5.4 The Design Cycle; 5.4.1 Analysis of the Source (Donor) Sequence; 5.4.1.1 Complementarity-Determining Regions (CDRs); 5.4.1.2 Canonical Residues; 5.4.1.3 Interface Packing Residues; 5.4.1.4 Rare Framework Residues; 5.4.1.5 N- or O-Glycosylation Sites; 5.4.2 Three-Dimensional Computer Modeling of the Antibody Structure; 5.4.3 Choice of Human Framework Sequences; 5.4.3.1 Fixed Frameworks or Best-Fit?; 5.4.3.2 VL/VH Frameworks from the Same or Different Clone?; 5.4.3.3 Human Subgroup Consensus or Expressed Framework?
|
|
|
:
|
2.4.5.4 Cytotoxicity Assays2.4.5.5 Screening for Function; 2.4.6 Cloning; 2.4.7 Expansion and Freezing of Hybridoma Clones; 2.5 Purification and Modification of Monoclonal Antibodies; 2.5.1 Mass Culture and Purification of Monoclonal Antibody; 2.5.2 Fragmentation of Monoclonal IgG Antibodies; 2.5.3 Labeling of Monoclonal Antibodies; 2.6 Monoclonal Antibodies for Tumor Therapy; 2.6.1 Leukocyte Differentiation Antigens; 2.6.2 Epithelial Differentiation Antigens; 2.6.3 Mechanisms of Action of Monoclonal Antibodies; 2.6.4 Human Monoclonal Antibodies; 2.7 Outlook; References
|
|
|
:
|
Part I: Selecting and Shaping the Antibody MoleculeChapter 2 Selection Strategies for Monoclonal Antibodies; 2.1 Introduction; 2.2 Historical Remarks; 2.3 Antibody Structure and Function; 2.3.1 Membrane-Bound and Secreted Forms of Antibodies; 2.3.2 Monoclonal Antibodies; 2.4 Production of Monoclonal Antibodies; 2.4.1 Immunization; 2.4.2 Myeloma Cell Lines; 2.4.3 Cell Fusion; 2.4.4 Drug Selection of Hybridomas; 2.4.5 Screening Hybridoma Cultures for Specific Antibody; 2.4.5.1 Enzyme-Linked Immunosorbent Assay (ELISA); 2.4.5.2 Flow Cytometry; 2.4.5.3 Immunohistology and Immunocytology
|
| Abstract
|
:
|
Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content. Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoc
|
| Subject
|
:
|
Immunoglobulins-- Biotechnology
|
| Subject
|
:
|
Immunoglobulins-- Therapeutic use
|
| Subject
|
:
|
Immunopharmacology
|
| LC Classification
|
:
|
RM282.I44H36 2010
|
| Added Entry
|
:
|
Dübel, Stefan
|
|
|
:
|
Reichert, Janice M
|
| Added Entry
|
:
|
Ohio Library and Information Network
|